Dr. Thomas Schulz - Net Worth and Insider Trading
Dr. Thomas Schulz Net Worth
The estimated net worth of Dr. Thomas Schulz is at least $0 dollars as of 2024-10-02. Dr. Thomas Schulz is the Board of Directors of Bilfinger SE and owns about 0 shares of Bilfinger SE (XTER:GBF) stock worth over $0. Details can be seen in Dr. Thomas Schulz's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Dr. Thomas Schulz has not made any transactions after 2024-01-08 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Dr. Thomas Schulz
Dr. Thomas Schulz Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Dr. Thomas Schulz owns 1 companies in total, including Bilfinger SE (XTER:GBF) .
Click here to see the complete history of Dr. Thomas Schulz’s form 4 insider trades.
Insider Ownership Summary of Dr. Thomas Schulz
Ticker | Comapny | Transaction Date | Type of Owner |
---|---|---|---|
XTER:GBF | Bilfinger SE | 2024-01-08 | Board of Directors |
Dr. Thomas Schulz Latest Holdings Summary
Dr. Thomas Schulz currently owns a total of 1 stock. Dr. Thomas Schulz owns 0 shares of Bilfinger SE (XTER:GBF) as of January 8, 2024, with a value of $0.
Latest Holdings of Dr. Thomas Schulz
Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
---|---|---|---|---|---|
XTER:GBF | Bilfinger SE | 2024-01-08 | 0 | 48.40 | 0 |
Holding Weightings of Dr. Thomas Schulz
Dr. Thomas Schulz Form 4 Trading Tracker
According to the SEC Form 4 filings, Dr. Thomas Schulz has made a total of 4 transactions in Bilfinger SE (XTER:GBF) over the past 5 years, including 4 buys and 0 sells. The most-recent trade in Bilfinger SE is the acquisition of 3,000 shares on January 8, 2024, which cost Dr. Thomas Schulz around $103,020.
Insider Trading History of Dr. Thomas Schulz
- 1
Dr. Thomas Schulz Trading Performance
GuruFocus tracks the stock performance after each of Dr. Thomas Schulz's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Dr. Thomas Schulz is 12.95%. GuruFocus also compares Dr. Thomas Schulz's trading performance to market benchmark return within the same time period. The performance of stocks bought by Dr. Thomas Schulz within 3 months outperforms 2 times out of 4 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Dr. Thomas Schulz's insider trading performs compared to the benchmark.
Performance of Dr. Thomas Schulz
Dr. Thomas Schulz Ownership Network
Dr. Thomas Schulz Owned Company Details
What does Bilfinger SE do?
Who are the key executives at Bilfinger SE?
Dr. Thomas Schulz is the Board of Directors of Bilfinger SE. Other key executives at Bilfinger SE include and Board of Directors Matti Jäkel .
Bilfinger SE (XTER:GBF) Insider Trades Summary
Over the past 18 months, Dr. Thomas Schulz made 4 insider transaction in Bilfinger SE (XTER:GBF) with a net purchase of 19,450. Other recent insider transactions involving Bilfinger SE (XTER:GBF) include a net purchase of 3,000 shares made by Matti Jäkel ,
In summary, during the past 3 months, insiders sold 0 shares of Bilfinger SE (XTER:GBF) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Bilfinger SE (XTER:GBF) were sold and 22,450 shares were bought by its insiders, resulting in a net purchase of 22,450 shares.
Bilfinger SE (XTER:GBF)'s detailed insider trading history can be found in Insider Trading Tracker table.
Bilfinger SE Insider Transactions
Dr. Thomas Schulz Mailing Address
Above is the net worth, insider trading, and ownership report for Dr. Thomas Schulz. Currently GuruFocus does not have mailing address information for Dr. Thomas Schulz.